ZEMA Pharma Consulting ApS: Financial statements 2026
CVR: 42680427
Source: annual report 2026, Danish Business Authority
01/10/2025 – 30/09/2026
ZEMA Pharma Consulting ApS (CVR 42680427) has filed annual accounts for 2026. In 2026, the company reported a gross profit of DKK 73,493 and a net result of DKK -256,741 compared with DKK -216,744 the year before. That is a decrease of 28.1% compared with the year before. Equity in the 2026 report amounted to DKK 97,802. The solvency ratio was 71.7%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 73,493
- Profit/Loss
- DKK -256,741
- Equity
- DKK 97,802
- Total Assets
- DKK 136,404
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2026 | - | 73K | -257K | 98K | 1 |
| 2025 | - | 102K | -217K | 355K | 1 |
| 2024 | - | 131K | -282K | 571K | 1 |
| 2023 | - | 1.5M | 812K | 853K | 1 |
| 2022 | - | 1.1M | 790K | 830K | 1 |
Official annual report
Find more companies like ZEMA Pharma Consulting ApS
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorAbout ZEMA Pharma Consulting ApS
ZEMA Pharma Consulting ApS is a Danish company of the type Anpartsselskab based in Dyssegård, founded in 2021. The company is registered under the industry Virksomhedsrådgivning og anden ledelsesrådgivning. The management consists of Mads Torkild Hansen. The company is owned by Mads Torkild Hansen. The company has 1 employee (2026). In 2026, the company reported a gross profit of DKK 73,493 and a net result of DKK -256,741 compared with DKK -216,744 the year before. Equity in the 2026 report amounted to DKK 97,802.
